Accure vs AviClear: Two 1726 nm Acne Lasers, Different Endpoints, Clearances, and Costs

When patients with persistent inflammatory acne are offered a 1726 nm laser, the two names that come up are AviClear (Cutera) and Accure (Accure Acne, Inc.). Both wavelengths target lipid-rich sebaceous glands rather than melanin or hemoglobin. They do not share a treatment algorithm, a clearance date, or a published head-to-head trial.

AviClear is typically a three-session, treat-to-fluence protocol with sapphire contact cooling; oil- or cream-based topical anesthetics are contraindicated. Accure is typically a four-session, treat-to-temperature protocol with infrared monitoring and forced-air cooling; Standard Mode uses injectable local anesthesia. This page is the comparison. The dedicated AviClear evidence page remains AviClear: FDA clearance, evidence, and limits.

---

Direct Comparison: Accure vs AviClear at a Glance

---

Are Accure and AviClear Both FDA-Cleared in the US, and Which Was First?

Both devices are cleared by the United States Food and Drug Administration (FDA) through the 510(k) Premarket Notification pathway under Class II, Regulation Number 21 CFR 878.4810 (powered laser surgical instrument, product code GEX). Neither device is an FDA "approved" drug (such as oral isotretinoin) or a Premarket Approval (PMA) Class III implantable device. For an in-depth explanation of how FDA regulatory categories function in aesthetics, see our guide on FDA cleared vs FDA registered aesthetic devices.

The Clearance Timeline and First-to-Market Record

Marketing materials and clinic blogs frequently confuse the chronological order of these devices, occasionally claiming Accure was the "first FDA-cleared 1726 nm laser." This is factually incorrect regarding the United States market:

1. AviClear (Cutera): First US 510(k) for a 1726 nm sebaceous-gland laser on March 24, 2022 under K213461 for mild to severe inflammatory acne vulgaris. Cutera later received K230660 on June 6, 2023 for long-term treatment of mild, moderate, and severe inflammatory acne, and a further AviClear 510(k) K251149 on July 11, 2025. The public 510(k) database confirms Cutera, device name AviClear Laser System, product code GEX; it does not itself reprint a new indication sentence for K251149.
2. Accure (Accure Acne, Inc.): Initial US 510(k) on November 17, 2022 under K222109. Accure held a European CE Mark before US clearance, which is why some European writing predates US availability. On October 11, 2024, Accure received K242035 for long-term treatment of mild to severe inflammatory acne vulgaris.

Both platforms are now US-cleared 510(k) Class II devices for long-term inflammatory acne management. That is not a PMA, and it is not a ranking of which laser is “more FDA.” The useful differences are endpoint, session count, anesthesia, and the Accure tracking recall.

---

Treat-to-Fluence vs Treat-to-Temperature: The Mechanical Divide

The practical split is treat-to-fluence versus treat-to-temperature.

AviClear: Treat-to-Fluence with Contact Sapphire Cooling

AviClear doses to a preset energy density. The handpiece uses AviCool sapphire contact cooling.

• Published device comparisons place contact-plate cooling at approximately 0°C to 5°C before, during, and after each pulse — not a 2–4°C figure.
• Fluence is set in J/cm² (Skin Therapy Letter: maximum single-pulse 30 J/cm²; double-pulse 20 J/cm²), with pulse counts across zones rather than a live temperature target.
• A typical face treatment is a global first pass plus a second pass over active clusters. Clinician consensus used on this site describes about 250 to 300 pulses per session after a March 2024 protocol update — not a labeled dose.
• Published protocol time is about 30 minutes of treatment; some clinics quote 50–60 minutes with setup.

Accure: Treat-to-Temperature with Infrared Thermal Feedback

Accure uses live epidermal-temperature feedback rather than fluence alone:

• An infrared camera measures peak epidermal temperature (PET). Published comparison tables set the PET window at 40.0°C to 46.0°C by body site.
• Forced-air cooling protects the epidermis while the device drives toward that PET endpoint.
• Optical tracking maps treated versus untreated zones. That tracking system is also what FDA recall Z-0778-2024 named.
• Skin Therapy Letter describes Accure sessions as about 45 minutes. Clinic pages that sell the competing device sometimes quote 60–120 minutes; treat those as interested-party time estimates, not labeled duration.

---

Anesthesia Protocols: Why Numbing Cream Is Banned on AviClear but Injections Are Used for Accure

The contrasting endpoints produce different comfort rules. That is a device-use fact, not a ranking of which laser “hurts more.”

Why AviClear Prohibits Topical Numbing Creams

AviClear instructions and the contact-cooled 1726 nm consensus (Bhatia et al. / PMC12856072) contraindicate oil-, cream-, or emulsion-based topical anesthetics:

1. Residue can scatter or absorb 1726 nm energy at the surface and raise the risk of focal epidermal injury.
2. An oily film interferes with sapphire-plate contact cooling.

Patients commonly report mid-range discomfort (consensus visual analog scores around 5 to 6 out of 10), sharper over bony areas. Clinics that follow the consensus use oral analgesics the patient already tolerates, degreasing, and water coupling — not a numbered milligram protocol from this page. Follow the label and the treating clinician.

Why Accure Standard Mode Uses Injectable Anesthesia

Accure’s treat-to-temperature algorithm holds heat until PET is reached. Skin Therapy Letter describes two modes:

• Standard Mode: injectable local anesthesia (lidocaine with epinephrine, plus buffer in published descriptions).
• Boost Mode: topical anesthetic plus a different pulsing method — not a generic “oil-free cream is fine” rule. Ask which mode the clinic actually uses.

Do not treat either laser’s anesthesia protocol as a DIY recipe. Nerve blocks and topical anesthetics have their own risks; the device IFU and the injector’s protocol govern what is used.

---

Clinical Trial Evidence: How Do the Clearance Studies Compare?

There is no published randomized head-to-head trial of Accure versus AviClear. A claim that one laser is proven more effective than the other is marketing, not a comparative trial result.

The datasets also use different endpoints, so they are not interchangeable percentages.

AviClear pivotal cohort (Alexiades et al., JAAD 2023; K213461)

• Population: 104 subjects aged 16 to 40 at 7 US centers. Baseline disease: 81 moderate, 22 severe, 1 mild.
• Protocol: 3 treatments, 2 to 5 weeks apart.
• Primary endpoint: more than half of enrolled subjects achieving ≥50% reduction in inflammatory lesion count at 12 weeks after the third session. That binary responder bar is what supported clearance — it is not a mean percent reduction, and it is not an Investigator’s Global Assessment (IGA) score.
• Do not mix IGA with lesion-count responders. Skin Therapy Letter’s summary of Alexiades reports IGA-based figures (for example, 87% achieving IGA 1+ at 3 months and 93% IGA 1+ at 12 months). Those are not the same as “87% were lesion-count responders at 6 months.” Manufacturer follow-up durability claims (visible improvement around 90–92% at 6–12 months) remain company-supported until independently replicated.

Accure series (manufacturer communications + Skin Therapy Letter)

• Skin Therapy Letter states that Accure clinical figures it summarizes are preliminary and unpublished, including a 12-patient Standard Mode presentation (Tanghetti et al., ASLMS 2020) and larger open-label cohorts.
• Accure’s own long-term-clearance communications for K242035 cite about 70% mean inflammatory-lesion reduction at 6 months after four monthly treatments. That is a manufacturer mean, not a JAAD pivotal binary responder rate.
• Skin Therapy Letter also reports an unpublished Standard Mode series with about 82% mean lesion reduction at 12 weeks after four treatments, and Boost Mode medians that change over follow-up with incomplete long-term n (17 of 35 at later visits). Those numbers should not be averaged with AviClear’s 104-subject responder bar.

A 92% IGA 1+ rate and a 70% mean lesion-count reduction answer different questions. Neither figure is an individual guarantee.

---

Skin of Color Safety: Fitzpatrick IV–VI Considerations

For patients with deeper skin tones (Fitzpatrick skin phototypes IV, V, and VI), energy-based acne devices have historically carried significant danger. Traditional broad-spectrum devices (such as Intense Pulsed Light / IPL) and pigment-targeting vascular lasers (such as 532 nm KTP or 595 nm Pulsed Dye Lasers) rely heavily on hemoglobin or melanin absorption. In melanin-rich epidermis, optical energy is competitively absorbed by epidermal melanocytes, creating a high risk of thermal burns, hypopigmentation, and stubborn post-inflammatory hyperpigmentation (PIH).

Absorption at 1726 nm is higher in sebum lipids than in water and is low in epidermal melanin relative to pigment-targeting lasers. That is why these devices are structurally more attractive than IPL or 532/595 nm vascular lasers for Fitzpatrick IV–VI inflammatory acne — they are not melanin devices. They still deposit heat in dermis, so secondary inflammation and PIH remain possible.

• AviClear: Cleared across phototypes I–VI. The pivotal cohort included a range of skin types; published reports did not describe keloid or permanent dyschromia as a trial signal when cooling was maintained. That is not a promise of zero PIH.
• Accure: Also used across phototypes I–VI in manufacturer series. Live PET monitoring is a safety control against epidermal overheating; it does not erase inflammatory PIH risk.

A post-treatment inflammatory flare (“purge”) in the first weeks is described for both platforms. In skin of color, that flare still needs PIH-aware aftercare. 1726 nm treats active inflammatory lesions; it does not revise ice-pick or rolling scars — see acne scar treatments in skin of color.

---

The Accure Class 2 Recall: What Happened and Does It Matter?

On January 20, 2024, FDA posted Class 2 recall Z-0778-2024 (event 205151) for the Accure Laser System, model PFMS00004, 510(k) K222109, UDI-DI 08059173392230. The firm initiated the recall on December 6, 2023. The listing names specific serial numbers (including LAD0000- and PROT- prefixes). As retrieved in this review, the FDA recall record remains classified/open — it is not proof that every unit in the field has been closed out.

FDA and secondary recall abstracts describe the issue as possible spot-tracking misalignment, with a risk of delivering more energy than intended to a given area. That is a device-history fact, not an incidence rate, and it is not a reason to invent an AviClear-versus-Accure adverse-event comparison from MAUDE.

Patients booking Accure should ask:

• Whether the clinic’s serial number is on the Z-0778-2024 list.
• What field action (inspection, software, hardware) was documented for that unit.

A Class 2 recall means use of the violative product may cause temporary or medically reversible harm, or the probability of serious harm is remote. It does not mean Accure was withdrawn from the US market.

MAUDE narratives exist for both lasers. Report counts are not incidence and do not prove causality.

---

Candidacy: Who Should Skip 1726 nm Lasers Entirely?

1726 nm lasers are not a default for every acne presentation.

Go ahead only if the disease is primarily inflammatory (papules, pustules, nodules) and the patient understands three- or four-session cash-pay protocols, delayed peak improvement, and possible flare.

Usually skip, or sequence differently, if:

1. Purely comedonal acne

These devices do not extract keratin plugs. Start with topical retinoids on the acne treatment evidence ladder.

2. Severe nodulocystic acne that still needs a systemic conversation

1726 nm is not a guaranteed substitute for oral isotretinoin in confluent scarring cystic disease. Isotretinoin remains the disease-modifying option with the strongest remission literature; delaying it to “try the laser first” can cost scars. That is a sequencing question for a dermatologist, not a laser bake-off.

3. Recent isotretinoin

Do not use a generic 6- or 12-month wait as if it were a labeled AviClear/Accure contraindication. ASDS-era guidance has narrowed some waits for non-ablative devices, but this is still a wound-healing judgment. Details: isotretinoin aesthetic waiting periods.

4. Established atrophic scars

1726 nm treats living inflammatory lesions. It does not subcise tethers or rebuild ice-pick depressions.

5. Pregnancy and nursing

Both clearance programs excluded pregnant and lactating people. Defer energy treatment; this is missing gestational data, not a proven teratogen.

6. Truncal acne as the main complaint

Face-versus-trunk split data are thin for both devices. Accure uses site-specific PET with the same tip; AviClear truncal hardware has been described as in development in older reviews. Medical truncal therapy: back acne evidence.

---

Cost Comparison: Why 3 Sessions vs 4 Sessions Changes the Total Budget

These are cash-pay procedures. They are not a Medicare or commercial-plan acne benefit.

Clinic quotes in 2026 often land in the same $800–$1,000 per session band for both devices. The protocol length then changes the package:

• AviClear: 3 sessions → about $2,400–$3,000 (some high-cost markets quote ~$3,600).
• Accure: 4 sessions → about $3,200–$4,000.

That $600–$1,000 gap is session count, not proof that one device is “worth more.” Maintenance touch-ups, if needed, are extra. Get an all-in package quote, including what happens if a fourth AviClear visit or a fifth Accure visit is recommended.

---

Decision Matrix: How to Choose Between Accure and AviClear

Choose on protocol fit. Do not choose on which brochure says “FDA” louder.

Lean AviClear if you want three visits, shorter published chair time, contact cooling, and you want to avoid injectable nerve blocks — accepting that oil-based numbing cream is off-limits and that mid-range snap pain is expected.

Lean Accure if you specifically want a PET-endpoint device with live IR monitoring, you accept four visits and Standard Mode injections, and you have asked about recall Z-0778-2024 for that serial number.

Choose neither as a first move if the acne is comedonal, you need an isotretinoin conversation, you are pregnant, or you are buying scar revision.

AviClear’s earlier US clearance and the absence of a matching classified tracking recall in this review are regulatory-history facts. They are not comparative efficacy.

---

Questions to Ask Your Dermatologist or Provider

Before signing a contract or paying a multi-thousand-dollar deposit for 1726 nm acne laser therapy, bring these direct questions to your consultation:

1. "Is my acne predominantly inflammatory (papules, pustules, cysts) or comedonal (blackheads, whiteheads)?"
   Why to ask: If your acne is primarily comedonal, spending $3,000 on a 1726 nm laser is clinically inefficient compared to topical retinoid therapy.
2. "If offering Accure, which mode do you use (Standard with injectable anesthesia or Boost), and is this unit’s serial number on FDA recall Z-0778-2024 — and if so, what field action is documented?"
   Why to ask: Comfort, chair time, and whether the 2024 spot-tracking recall applies to the machine in the room.
3. "If offering AviClear, do you strictly adhere to the no-topical-numbing guideline and what comfort measures do you provide?"
   Why to ask: Ensures the clinic understands optical safety and does not apply hazardous oily compounding creams prior to treatment.
4. "What is the total, all-inclusive package price for the complete protocol (3 sessions for AviClear, 4 for Accure), and what is the fee policy if a touch-up session is required at 6 or 12 months?"
   Why to ask: Prevents hidden add-on facility fees and clarifies long-term maintenance costs.
5. "How will we coordinate my ongoing topical skincare routine during and after the laser series?"
   Why to ask: Most patients benefit from maintaining a gentle barrier-repair regimen and low-irritation actives during the therapeutic window.

---

Sources

• FDA 510(k) Premarket Notification Database, AviClear Laser System (K213461), Decision Date March 24, 2022: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K213461
• FDA 510(k) Premarket Notification Database, Accure Laser (K222109), Decision Date November 17, 2022: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K222109
• FDA 510(k) Premarket Notification Database, AviClear Laser System Long-Term Indication (K230660), Decision Date June 6, 2023: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?id=K230660
• FDA 510(k) Premarket Notification Database, Accure Laser System Long-Term Treatment Clearance (K242035), Decision Date October 11, 2024: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K242035
• FDA 510(k) Premarket Notification Database, AviClear Laser System (K251149), Decision Date July 11, 2025: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K251149
• FDA Medical Device Recall Database, Class 2 Recall Z-0778-2024 Accure Laser System Model PFMS00004 Spot-Tracking System: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?id=205151
• Skin Therapy Letter, 1726 nm Lasers for the Treatment of Acne Vulgaris (Comparative Mechanism, Endpoints, and Clinical Series): https://www.skintherapyletter.com/acne/1726-nm-lasers
• Alexiades M, et al. Novel 1726 nm laser demonstrates durable therapeutic outcomes and tolerability for moderate-to-severe acne across skin types. J Am Acad Dermatol. 2023;89(4):703-710: https://doi.org/10.1016/j.jaad.2023.05.085
• PMC: Consensus Panel Recommendations for a Contact-Cooled 1726 nm Laser for the Treatment of Acne: https://pmc.ncbi.nlm.nih.gov/articles/PMC12856072
• FDA Aesthetic Cosmetic Devices Index and Regulatory Guidance: https://www.fda.gov/medical-devices/products-and-medical-procedures/aesthetic-cosmetic-devices
• ClinicalTrials.gov Registry, 1726 nm Laser Clinical Study Inventory (National Library of Medicine): https://clinicaltrials.gov